#Ep 5: The Consistent Compounders Show :Stay tuned to catch Saurabh Mukherjea in conversation with Sohini Andani, Fund Manager, SBI Mutual Fund.
you are here: HomeNewsBusiness

Coronavirus pandemic | M&M hopes to be ready with ventilator prototype in 3 days

The company said it is also working with two large PSUs along with an existing manufacturer of high spec ventilators to help them simplify design and scale up capacity.

March 26, 2020 / 03:04 PM IST
Representative image

Representative image

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Mahindra & Mahindra today said it hopes to have a prototype of an automated version of bag valve mask ventilator, commonly known as Ambu bag, in three days for approval to assist in combating the coronavirus pandemic.

The company said it is also working with two large PSUs along with an existing manufacturer of high spec ventilators to help them simplify design and scale up capacity.

Sharing the company's two-pronged approach in its efforts to prevent shortage of ventilators, M&M Managing Director Pawan Goenka said,"At one end, we along with two large PSUs are working with an existing manufacturer of high spec ventilators to help them to simplify design and scale up capacity. Our engineering team is right now with them working on it."

In a series of tweets, he further said,"at other end we are working on an automated version of the Bag Valve Mask ventilator (commonly known as Ambu bag). We hope to have a Proto ready in three days for approval. Once proven this design will be made available to all for manufacturing."

On March 22, Mahindra Group Chairman Anand Mahindra had said to help in the response to the unprecedented coronavirus threat, Mahindra Group will immediately begin work on how its manufacturing facilities can make ventilators.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
Goenka said,"We at Mahindra are overwhelmed with pouring in of support from individuals and companies for our effort to make available ventilators."  Mahindra had also offered the facilities of the group's hospitality arm.
PTI
first published: Mar 26, 2020 02:32 pm

stay updated

Get Daily News on your Browser
Sections